$XLO Reports Initial Data From Ongoing Phase 2 Clinical Trial Evaluating Vilastobart In Combination With Atezolizumab; 27% Preliminary Response Rate Observed In Heavily Pre-Treated Microsatellite Stable Colorectal Cancer Patients Without Liver MetastasesXilio Therapeutics has reported initial data from its ongoing Phase 2 clinical trial evaluating vilastobart in combination with atezolizumab. The trial focuses on patients with heavily pre-treated microsatellite stable (MSS) colorectal cancer without liver metastases. A preliminary response rate of 27% was observed in this patient group. The data suggests potential efficacy of the combination therapy in a challenging patient population. Vilastobart is being assessed for its ability to enhance the immune response. Atezolizumab, an anti-PD-L1 antibody, is already used in cancer treatments. The results offer encouraging signs for this combination therapy in MSS colorectal cancer. Xilio plans further analysis to confirm and expand on these findings. #StockMarket
#xlo
#XLO